As of May, 10 The EPS for Knight Therapeutics Inc. (GUD) Expected At $0.03

May 3, 2018 - By Alice Reed

Knight Therapeutics Inc. (TSE:GUD) Corporate Logo

On May, 10 is anticipated Knight Therapeutics Inc. (TSE:GUD)’s earnings report, as reported by Faxor. Analysts forecast $0.03 EPS, which is $0.01 down or 25.00 % from 2017’s $0.04 EPS. If EPS of $0.03 is reported the profit of T_GUD could reach $4.29M giving it 66.08 P/E. Analysts at Wall Street see Knight Therapeutics Inc.’s -40.00 % negative EPS growth compared to $0.05 EPS for last quarter. GUD is reaching $7.93 during the last trading session, after increased 0.51%.Knight Therapeutics Inc. has volume of 30,888 shares. Since May 3, 2017 GUD has 0.00% and is . GUD underperformed by 11.55% the S&P500.

Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally.The company has $1.13 billion market cap. The company's commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement.The P/E ratio is 66.08. The Company’s products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: